Lenzilumab
Modify Date: 2025-08-26 17:27:12
Lenzilumab structure
|
Common Name | Lenzilumab | ||
|---|---|---|---|---|
| CAS Number | 1229575-09-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LenzilumabLenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2]. |
| Name | Lenzilumab |
|---|
| Description | Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1]. Animal Model: NSG mice with CART19 cells[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; daily; 10 days Result: Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |
| References |
| No Any Chemical & Physical Properties |